



Updated Monthly

July 10, 2024

Prepared for:



THE ESSENTIAL GUIDE TO

Non-Dilutive Government Funding

Published by:




Questions?

Liz Powell, Esq., MPH

lpowell@G2Gconsulting.com

www.G2Gconsulting.com

  @G2Gconsulting





GBG Report

Updated Monthly

July 10, 2024

<https://www.g2gconsulting.com/gbg-reporting-service/>

TABLE OF CONTENTS

New Opportunities

Artificial Intelligence & Machine Learning	2
Biotechnology and Biomanufacturing.....	2
Cancer	3
Cardiovascular and Pulmonary Health.....	4
Chronic Disease	5
Cognitive and Brain Health.....	5
Combat Casualty Care.....	6
Cybersecurity.....	6
Dental and Craniofacial Research	6
Genomics	7
Health IT & Data.....	7
HIV/AIDS	7
Holistic Health	8
Immunology & Infectious Disease	8
Measurement Science	10
Medical Countermeasures.....	10
Mental Health.....	10
Microbiome Research.....	10
Neurofibromatosis.....	11

Patient-Centered Research	11
Reconstructive Transplant	11
Research Support	12
Small Business Development	12
Substance Use.....	14
Therapeutics.....	15
Toxic Exposures	16
Warfighter Performance	16

Recurring Opportunities

Advanced Research Projects Agency for Health	17
Air Force	18
Army.....	18
BARDA	20
DARPA	20
Defense Threat Reduction Agency	21
Department of Energy.....	21
Navy	21
National Science Foundation	22
GBG Acronyms	23



July 18, 2024 – Join us for G2G’s Monthly [Non-Dilutive Funding: GBG Reporting Service Webinar](#) at 12-12:30pm EDT (FREE to all) and 12:30-1:00pm (premium service private consultation for G2G and GBG clients). If you’re an affiliate of BioUtah, Bio Nebraska, Focused Ultrasound Foundation, iBIO, Indiana Health Industry Forum, IowaBio, MichBio, NCBiotech, Ohio Life Sciences, South Dakota Biotech, or VaBio – your membership gets you access to the private consultation webinar.

Navigating MHSRS 2024, DoD & Funding Opportunities: MHSRS 2024 will be held from August 26-29 at the Gaylord Palms Resort & Convention Center in Kissimmee, FL. [Registration is open now](#). Finalize your strategy for this essential conference with G2G’s webinar on Wednesday, July 17 at noon EDT. [Register here](#).

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARTIFICIAL INTELLIGENCE & MACHINE LEARNING (2)		
1.	Pitching AI for Pharmaceutical R&D QuickFire Challenge (J&J)	This challenge seeks: novel strategies and approaches to harness AI to accelerate or automate pharmaceutical R&D. Selected applicants will be invited to showcase their innovation to Johnson & Johnson's Innovative Medicine R&D Data Science & Digital Health leadership at the West Coast Summit: The Transformative Power of AI in Pharmaceutical R&D. https://ijninnovation.com/innovation-challenges/Pitching-AI-for-Pharmaceutical-RnD-QuickFire-Challenge	N/A	Proposal: 8/2/24
2.	NASA Breath Diagnostics Challenge (NASA)	The objective of this challenge is to develop a diagnostic model by using NASA E-Nose data gathered from exhaled breath of 63 volunteers in a COVID-19 study. Challenge participants will use advanced data preparation and AI techniques to overcome the limited sample size of subjects in the COVID-19 study. https://bitgrit.net/competition/22	Total prizes of \$55,000	Proposal: 9/6/24
		BIOTECHNOLOGY AND BIOMANUFACTURING (2)		
3.	Industrial Base Expansion of injection molded pipette tips and centrifuge tubes (BARDA/BioMaP) 24-06-Pipette	ASPR seeks to engage with an industry partner, on a cost sharing basis, to expand domestic manufacturing capacity of injection molded plastic pipette tips and centrifuge tubes. These pharmaceutical consumable products are components of many types of end products used in the biomanufacturing process, for which the supply chain is currently unable to meet pandemic surge demands. https://www.biomap-consortium.org/rpp-24-06-pipette/	Dependent upon proposal and available funds	Proposal: 7/25/24

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOTECHNOLOGY AND BIOMANUFACTURING		
4.	Switch (DoD/DARPA) DARPA-PS-24-16	DARPA is soliciting innovative proposals to develop biomanufacturing platforms for run-time reprogramming of chemical synthesis operations, which will enable new Concepts of Operations (CONOPS) that provide novel capabilities for national security. Switch is focused on bringing programmability and long-term stability to biomanufacturing processes, with the goal of enabling more flexible chemical manufacturing operations that can toggle between different feedstocks or products over continuous production runs. https://sam.gov/opp/e03b50a1ea6942ce8516260086dc497e/view	Up to \$300,000 (Phase 0) Up to \$8 million (Phase I)	Abstract: 7/31/24 Oral Proposal Package: 8/21/24 Oral Presentation: 9/16-20/24
		CANCER (13)		
5.	FY24 Kidney Cancer Research Program (KCRP) (DoD/CDMRP) HT942524KCRPAKCILA (AKCILA) HT942524KCRPCA (CA) HT942524KCRPPCFA (PCFA)	Three of the seven anticipated awards have been posted: Academy of Kidney Cancer Scholars - Leadership Award; Concept Award; and Postdoctoral and Clinical Fellowship Award. All applications must address one or more of the Focus Areas . https://cdmrp.health.mil/funding/kcrp	Up to \$1.5 million, for up to 5 years Dependent upon award mechanism	Pre-Application: 8/29/24 Proposal: 9/19/24 (AKCILA) Pre-Application: 8/15/24 Proposal: 9/5/24 (CA/PCFA)
6.	FY24 Peer Reviewed Cancer Research Program (DoD/CDMRP) HT942524PRCRPACCTA (ACCTCTA) HT942524PRCRPCSCCA (CSCCA) HT942524PRCRPVCCDA (VCCDA)	The remaining three of the seven anticipated awards have been posted: Advancing Clinical Care Through Clinical Trials Award; Convergent Science Cancer Consortium Award; and Virtual Cancer Center Director Award. Applications must address at least one of FY24 PRCRP Topic Areas, and at least one of the following Military Health Focus Areas: Environmental/exposure risk factors associated with cancer; Gaps in cancer research that may affect mission readiness. https://cdmrp.health.mil/funding/prcrp	Up to \$20 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 9/24/24 Proposal: 10/15/24
7.	NOSI: Advancing Diet and Physical Activity Biomarkers for Assessing Lifestyle Interventions in Cancer Prevention and Cancer Interception Research (NIH/NCI) NOT-CA-24-060	This NOSI supports applications improving diet and/or physical activity assessment biomarker development for evaluating lifestyle-based cancer prevention and interception approaches across diverse settings. https://grants.nih.gov/grants/guide/notice-files/NOT-CA-24-060.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/7/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
8.	NOSI: Factors impacting how Time-Restricted Eating (TRE) influences cancer-related outcomes (NIH/NCI) NOT-CA-24-073	There are important unanswered questions as to whether adhering to a TRE dietary strategy will improve metabolic outcomes and lower cancer risk, improve cancer treatment response and outcomes, and/or improve other obesity and cancer-related outcomes, including among long-term cancer survivors. Intermediate markers and health outcomes such as insulin sensitivity and inflammation can be used as endpoints given the importance of such factors in mediating obesity and cancer-related outcomes. https://grants.nih.gov/grants/guide/notice-files/NOT-CA-24-073.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 5/7/27
9.	Forecast: Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT)-Lung Cancer Screening (UG3/UH3 Clinical Trial Required) (NIH/NCI) NOT-CA-24-075	Each SUMMIT LCSResearch Project will advance the science of scale-up and sustainment by testing strategies to increase and sustain the delivery of high-quality guideline concordant LCS among populations at high-risk for lung cancer. https://grants.nih.gov/grants/guide/notice-files/NOT-CA-24-075.html	Up to \$500,000 per year, for up to 2 years (UG3) Up to \$850,000 per year, for up to 4 years (UH3)	Estimated post date: 8/19/24 Estimated proposal date: 11/15/24
10.	Pitching ADC Advancements QuickFire Challenge (J&J)	This challenge seeks: Preclinical or clinical stage novel, differentiated ADCs with superior safety and efficacy against validated and novel targets in bladder cancer, colorectal cancer, lung cancer, prostate cancer and/or hematologic malignancies. Selected innovators will receive the opportunity to pitch their science to Johnson & Johnson's Innovative Medicine Oncology R&D leaders in a series of closed-door virtual pitch sessions. https://jninnovation.com/innovation-challenges/Pitching-ADC-Advancements-QuickFire-Challenge	N/A	Proposal: 8/30/24
		CARDIOVASCULAR AND PULMONARY HEALTH (2)		
11.	Phased Multi-Site Clinical Trial: Testing Prevention of Cardiovascular Disease in Young Adults With High Lifetime Risk Using Surrogate Outcomes – DCC and CCC (Collaborative U24/UG3/UH3 CT Required) (NIH/NHLBI) RFA-HL-25-007 (U24) RFA-HL-25-010 (UG3/UH3)	These NOFOs support a clinical trials which will test intervention(s) to reduce the progression of coronary atherosclerosis among young adults who are at low or borderline 10-year risk (<7.5%) for their first atherosclerotic cardiovascular disease (ASCVD) event, yet at high lifetime risk of developing cardiovascular disease (CVD). For the purpose of this NOFO, “young adults” is defined as less than or equal to 50 years for men, and given the lower rate of coronary atherosclerosis before menopause for women compared to men, it may be reasonable to use an expanded inclusion criteria to include women older than age 50. https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-25-007.html (U24) https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-25-010.html (UG3/UH3)	Up to \$5.6 million, for up to 7 years (U24) Up to \$22.5 million, for up to 7 years (UG3/UH3)	Letter of intent: 9/9/24 Proposal: 10/28/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CHRONIC DISEASE (2)		
12.	Forecast: Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01/R21 - Clinical Trial Optional) (NIH/NINDS/NIMH/ORWH) NOT-NS-24-105 (R01) NOT-NS-24-108 (R21)	These NOFOs will solicit applications focused on the neurological and psychiatric manifestations of infection-associated chronic illnesses, including the post-acute sequelae of COVID-19 (Neuro-PASC) as well as other chronic illnesses with a potential infectious trigger. Projects that investigate common neuropsychiatric mechanisms across multiple infection-associated chronic illnesses would be of particular interest, although this is not a requirement. https://grants.nih.gov/grants/guide/notice-files/NOT-NS-24-105.html (R01) https://grants.nih.gov/grants/guide/notice-files/NOT-NS-24-108.html (R21)	Up to \$500,000 per year (R01) Up to \$275,000, for up to 2 years (R21)	Estimated post date: 10/28/24 Estimated proposal date: 2/3/25
		COGNITIVE AND BRAIN HEALTH (5)		
13.	Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) (NIH/NIA) PAR-24-223	This NOFO invites applications proposing pre-clinical and early stage clinical development of novel small-molecule and biologic drug candidates that aim to prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. https://grants.nih.gov/grants/guide/pa-files/PAR-24-223.html	Up to \$1.5 million per year, for up to 5 years	Multiple deadlines; NOFO open through 11/5/27
14.	Interaction Between Environmental Factors and Lewy Body Dementia (R01 - Clinical Trial Not Allowed) (NIH/NINDS/NIA) PAR-24-249	This NOFO supports research that establishes causal links between a range of environmental factors and Lewy body formation. These factors include exposures to environmental toxicants, light and noise, climate, and other external exposures. This NOFO will support mechanistic, translational, and human subject studies to understand the relationship between environmental factors and LBD. https://grants.nih.gov/grants/guide/pa-files/PAR-24-249.html	Up to \$500,000 per year, for up to 5 years	Letter of intent: 9/4/24 Proposal: 10/4/24
15.	Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required) (NIH/NIA) RFA-AG-25-010	This NOFO invites applications to develop and implement multi-site Phase Ib to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of Alzheimer's disease (AD) and other age-related dementias using the Alzheimer's disease Clinical Trials Consortium (ACTC) trial coordination and management infrastructure. https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-010.html	Dependent upon proposal, for up to 5 years	Proposal: 10/17/24
16.	Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional) (NIH/NIA) RFA-AG-25-011	The purpose of this NOFO is to 1) invite applications that propose to develop and implement early- to late-stage clinical trials of promising pharmacological and non-pharmacological interventions to prevent and/or treat the cognitive, behavioral, and neuropsychiatric changes associated with age-related cognitive decline and AD/ADRD, and 2) stimulate studies to enhance trial design and methods. https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-011.html	Dependent upon proposal, for up to 5 years	Letter of intent: 8/8/24 Proposal: 10/17/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COGNITIVE AND BRAIN HEALTH		
17.	BRAIN Initiative: Brain Behavior Quantification and Synchronization (R61/R33 Clinical Trial Optional) (NIH) RFA-MH-26-100	This NOFO supports the development and validation of next-generation tools, methods, and analytic approaches to precisely quantify behaviors and combine them with simultaneous recordings of brain activity in humans. https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-26-100.html	Dependent upon proposal, for up to 5 years	Letter of intent: 12/22/24 Proposal: 1/22/25
		COMBAT CASUALTY CARE (1)		
18.	Thunderstorm 24-4: Expeditionary Operations (DoD) IM-20240627-W-Thunderstorm_24-4	Thunderstorm 24-4 is an invitation-only field technology showcase, focusing on innovative solutions for expeditionary operations. One of the focus capabilities is: Advanced medical solutions for immediate care in the field, and solutions that support the health and readiness of deployed personnel. Emphasis is on life-saving interventions, rapid evacuation capabilities, and portable medical devices. https://sam.gov/opp/79513913aef541ddab9f9575b4d7ad26/view	N/A	Application: 8/9/24 Event: 11/4-8/24, Fredericksburg, VA
		CYBERSECURITY (1)		
19.	Universal PatchinG and Remediation for Autonomous DEfense (UPGRADE) Virtual Proposers' Day (ARPA-H) ARPA-H-MAI-24-01-05	UPGRADE aims to fund the creation of vulnerability mitigation tools that act as a force multiplier for hospital IT/cybersecurity teams, dramatically advancing hospitals' capacities to understand, source, plan, and deploy security upgrades for connected hospital equipment. https://sam.gov/opp/dae88ab1ce714bb6baefcf998cb5508c/view	Dependent upon proposal and award mechanism	Solution Summary: 7/22/24 Proposal date: 9/18/24
		DENTAL AND CRANIOFACIAL RESEARCH (6)		
20.	NOSI: NIDCR Support for Research on Understanding Phage Biology in the Oral Cavity (NIH/NIDCR) NOT-DE-24-014	This NOSI aims to encourage research to better understand bacteriophage biology in the oral cavity and to support eventual development of therapeutics. https://grants.nih.gov/grants/guide/notice-files/NOT-DE-24-014.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/7/28
21.	Forecast: TMD Collaborative for IMproving PATient-Centered Translational Research (TMD IMPACT) (U54 Clinical Trial Optional) (NIH/NIDCR) NOT-DE-25-029	The purpose of TMD IMPACT is to establish a national, interdisciplinary, patient-centered research collaborative that will advance TMD basic and clinical research, research training, and translation to evidence-based treatments and improved clinical care. https://grants.nih.gov/grants/guide/notice-files/NOT-DE-25-029.html	Up to \$3.5 million	Estimated post date: 8/30/24 Estimated proposal date: 12/13/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		GENOMICS (1)		
22.	Broad-Spectrum Antagonists for Editors (B-SAFE) (DoD/DARPA) HR001124S0032	The DARPA BSAFE program aims to develop platform technologies for highly potent inhibitors for multiple classes, types, and species of editors with enhanced activity, utility, and breadth of coverage. The B-SAFE program will also address the challenge of inhibitor molecules keeping pace with the discovery of novel editing systems by developing a platform for rapid discovery and development of inhibitors of novel, emergent gene editor technologies. https://sam.gov/opp/5f73920279b745a491b865013ad749c8/view	Dependent upon proposal and award mechanism	Abstract: 7/15/24 Proposal: 8/12/24
		HEALTH IT & DATA (2)		
23.	Standardizing Data and Metadata from Wearable Devices (R01 Clinical Trial Not Allowed) (NIH/NIMH) PAR-24-250	Wearable technology shows promise in providing information that can be used to create biomarkers of various diagnostic groups that have relevance to mental illness. This NOFO supports the creation of standards for data as well as metadata and related coordination activities that will allow researchers to easily access data from personal tracking devices and integrate those data for subsequent data analysis. https://grants.nih.gov/grants/guide/pa-files/PAR-24-250.html	Dependent upon proposal, for up to 4 years	Multiple deadlines; NOFO open through 6/10/26
24.	D-START: Data Science Track Award for Research Transition (D/START) (R03-Clinical Trial Optional) (NIH/NIDA) PAS-24-242	This NOFO seeks to support investigators interested in applying cutting-edge data science techniques to address timely and challenging research questions related to substance use and/or SUD in all areas of research supported by NIDA. https://grants.nih.gov/grants/guide/pa-files/PAS-24-242.html	Up to \$100,000 per year, for up to 2 years	Multiple deadlines; NOFO open through 9/7/27
		HIV/AIDS (4)		
25.	Mechanisms of Inducing HIV Immunity in Early Life (MIEL) (U01 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AI-24-029	This NOFO supports basic and applied research to define the mechanisms for establishing, developing and maintaining immunity to HIV in early life (from birth to less than 12 years of age), including the impact of prophylactic vaccination and broadly neutralizing HIV antibodies (bNAbs) to protect against acquisition of HIV infection. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-029.html	Up to \$750,000 per year, for up to 5 years	Letter of intent: 9/9/24 Proposal: 10/9/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HIV/AIDS		
26.	Mechanisms of Reciprocal Interactions between HIV Associated Neuroinflammation and CNS Persistence: Implications in HIV Neuropathogenesis and Cure (R01/R21 CT Not Allowed) (NIH/NIMH/NIDA/NINDS) RFA-MH-25-180 (R01) RFA-MH-25-181 (R21)	The goal of these NOFOs is to examine mechanisms of reciprocal interactions between HIV-associated neuroinflammation and CNS HIV persistence. They encourage research focused on defining the role and mechanisms of defective proviruses, HIV proteins and/or nucleic acids in inducing inflammation, immune activation and CNS co-morbidities. https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-25-180.html (R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-25-181.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)	Letter of intent: 10/8/24 Proposal: 11/8/24
27.	Novel Preclinical Models of NeuroHIV in the cART Era (R61/R33 - Clinical Trial Not Allowed) (NIH/NINDS/NIDA/NIMH) RFA-NS-24-035	This initiative will solicit applications that propose the development and early stage validation of novel small animal models and/or human cellular microphysiological systems of HIV infection that better recapitulate the complex interactions that occur between cells of the CNS and the immune system in people with HIV (PWH). https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-035.html	Up to \$600,000 per year, for up to 4 years	Letter of intent: 11/1/24 Proposal: 12/2/24
		HOLISTIC HEALTH (1)		
28.	Whole Person Research and Coordination Center (Whole Person RCC) U24 (Clinical Trial Not Allowed) (NIH) RFA-AT-24-010	This center will be integral in coordinating the initial and future research programs in whole person health research. Its creation is driven by the goal to seamlessly integrate current and emerging biomedical knowledge about human health, thereby forming a comprehensive, multi-scale human knowledge network. https://grants.nih.gov/grants/guide/rfa-files/RFA-AT-24-010.html	Up to \$1.5 million per year, for up to 5 years	Letter of intent: 10/1/24 Proposal: 11/1/24
		IMMUNOLOGY & INFECTIOUS DISEASE (12)		
29.	Manufacturing Optimization for Filovirus Monoclonal Antibodies (BARDA/BioMaP) 24-07-mAbs	BARDA is seeking to augment the USG's response capabilities with therapeutics targeting filovirus disease caused by Ebola virus (EBOV), Marburg virus (MARV), or Sudan virus (SUDV). There are currently two US Food and Drug Administration (FDA) approved therapeutics for treatment of Ebola Virus Disease (EVD), Inmazeb and Ebanga, both of which are monoclonal antibodies or antibody cocktails. There are no therapeutics approved for the treatment of patients infected with SUDV or MARV. BARDA is interested in advancing manufacturing development for a monoclonal antibody (mAb) cocktail composed of two mAbs. https://www.biomap-consortium.org/rpp-24-07-mabs/	Dependent upon proposal and available funds	Proposal: 7/22/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		IMMUNOLOGY & INFECTIOUS DISEASE		
30.	NOSI: Epigenetic Modulation of HBV cccDNA and integrated HBV DNA (iDNA): Implications for Epigenetic Treatment Strategies Against HBV in HIV/HBV Co-Infection (NIH/NIAID) NOT-AI-24-050	This NOSI invites applications for innovative basic, translational, and clinical research to identify and address epigenetic treatment strategies for achieving HBV cure in PLWH. This NOSI will support studies on (1) the epigenetic mechanisms regulating HBV cccDNA and iDNA in the presence of HIV; and (2) targeting epigenetic pathways for achieving HBV cure. https://grants.nih.gov/grants/guide/notice-files/NOT-AI-24-050.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 5/7/27
31.	NOSI: Discovery and Development of Oral Small-molecule Direct-acting Antivirals Targeting Viruses of Pandemic Potential (NIH/NIAID) NOT-AI-24-053	This NOSI invites applications focused on the preclinical discovery, evaluation and development of oral direct-acting small molecule therapeutics targeting selected viruses of pandemic potential. The ultimate goal of this NOSI is to build a more robust pipeline of candidate antiviral drugs suitable for widespread use in the community in future outbreaks and/or pandemics. https://grants.nih.gov/grants/guide/notice-files/NOT-AI-24-053.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 7/16/27
32.	Promoting Innovative Research in Treponema pallidum Pathogenesis (R21 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AI-24-045	This NOFO supports basic and exploratory research projects to advance our understanding of Treponema pallidum bacterial pathogenesis. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-045.html	Up to \$275,000, for up to 2 years	Letter of intent: 10/4/24 Proposal: 11/4/24
33.	Central Influenza Virus and Emerging Infectious Disease Immunogenicity Laboratory Services (BARDA/RRPV) RPP-24-07-CentralIEIDLab	To address a capability readiness gap that has been identified within BARDA's product portfolio responding to a viral pandemic event, BARDA is seeking to partner with laboratories with existing capabilities to perform centralized immune assays using samples collected from nonclinical studies and from subjects enrolled in influenza, SARS-CoV, and emerging infectious disease vaccine clinical trials conducted under the U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) applications and to perform cross-reactive immune response testing of clinical samples for pandemic preparedness and response. https://www.rrpv.org/solicitation/rpp-24-07-centralieidlab/	Dependent upon proposal and award mechanism	Proposal: 7/15/24
34.	Leveraging Technology to Drive Representative Clinical Trials QuickFire Challenge (J&J)	Innovators from around the globe are invited to submit tools, platforms, technologies, or methods to enhance diversity, equity, and inclusion in clinical studies with the goal to increase patient representation for global clinical trials focused on immune-mediated diseases. https://jnjinovation.com/innovation-challenges/Leveraging-Technology-to-Drive-Representative-Clinical-Trials-Quickfire-Challenges	Total funds of \$250,000	Proposal: 9/13/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MEASUREMENT SCIENCE (1)		
35.	Standardization Center of Excellence (DoC/NIST) 2024-NIST-SCOE-01	The SCoE will support U.S. engagement in international standardization for critical and emerging technologies (CETs) that are essential to U.S. economic competitiveness and national security. The SCoE will focus on four broad areas: 1) pre-standardization engagement; 2) workforce capacity building; 3) a collaborative pilot program with NIST in CETs; and 4) creating an information and data sharing hub. https://grants.gov/search-results-detail/355227	Up to \$3 million per year, for up to 5 years	Proposal: 8/7/24
		MEDICAL COUNTERMEASURES (1)		
36.	CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System (R01 CT Not Allowed) (NIH/NINDS/NIAID) PAR-24-030	This NOFO invites applications for basic research to inform toxicology of chemical warfare agents and select toxic industrial chemicals and materials that have primary or secondary effects on the nervous system. https://grants.nih.gov/grants/guide/pa-files/PAR-24-030.html	Up to \$300,000 per year, for up to 3 years	Multiple deadlines; NOFO open through 10/16/26
		MENTAL HEALTH (1)		
37.	Individually Measured Phenotypes to Advance Computational Translation in Mental Health (IMPACT-MH) (U01 Clinical Trial Optional) (NIH/NIMH) RFA-MH-25-195	This NOFO is intended to stimulate and support research that will use behavioral measures and computational methods to define novel clinical signatures that can be used for individual-level prediction and clinical decision making in mental disorders. https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-25-195.html	Up to \$2.5 million per year, for up to 5 years	Letter of intent: 9/18/24 Proposal: 10/18/24
		MICROBIOME RESEARCH (3)		
38.	Draft: Predictions for Real-time Optimization of MICRObiomes of Built Environments (PRO-MICROBE) (ARPA-H) ARPA-H-MAI-24-01-06	By creating new ways to assess and predict the impact of indoor microbial communities on occupant health outcomes, PRO-MICROBE seeks to transform how building design and engineering can support microbial communities important for optimal human health while resisting the colonization of pathogenic microorganisms. https://sam.gov/opp/57f48c8948fo47de834792203dd5a741/view	Dependent upon proposal and award mechanism	Response: 8/30/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MICROBIOME RESEARCH		
39.	Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional) (NIH) PAR-24-238 (R61/R33) PAR-24-239 (R33)	These NOFOs support highly innovative mechanistic research to accelerate the development of effective precision probiotic interventions using a milestone-driven, biphasic award mechanism. They aim to identify, understand, and develop strategies to address barriers in precision probiotic interventions to account for the heterogeneity in humans that often causes inconsistent probiotic therapeutic responses. https://grants.nih.gov/grants/guide/pa-files/PAR-24-238.html (R61/R33) https://grants.nih.gov/grants/guide/pa-files/PAR-24-239.html (R33)	Up to \$350,000 per year, for up to 5 years (R61/R33) Up to \$350,000 per year, for up to 4 years (R33)	Multiple deadlines; NOFOs open through 6/2/27
		NEUROFIBROMATOSIS (6)		
40.	FY24 Neurofibromatosis Research Program (DoD/CDMRP) HT942524NFRPCTA (CTA) HT942524NFRPEIRA (EIRA) HT942524NFRPEHDA (EHDA) HT942524NFRPIIRA (IIRA) HT942524NFRPNIA (NIA) HT942524NFRPSIA (SIA)	The remaining six anticipated awards have been posted: Clinical Trial Award, Early Investigator Research Award, Exploration-Hypothesis Development Award, Investigator-Initiated Research Award, New Investigator Award, and Synergistic Idea Award. All applications must address at least one of the Areas of Emphasis . https://cdmrp.health.mil/funding/nfrp	Up to \$2 million, for up to 3 years Dependent upon award mechanism	Pre-Application: 9/12/24 Proposal: 10/3/24
		PATIENT-CENTERED RESEARCH (1)		
41.	Implementing and Evaluating Patient-Centered Clinical Decision Support Strategies in Real-World Settings (U18) (HHS/AHRQ) RFA-HS-24-003	This NOFO aims to support innovative collaborative research to understand how clinical decision support tools in real-world settings can be improved to become more patient centered. Recipients will become part of an existing community of researchers who have an interest in PC CDS including AHRQ, the CDSiC, and other researchers. https://grants.nih.gov/grants/guide/rfa-files/RFA-HS-24-003.html	Up to \$500,000 per year, for up to 2 years	Letter of intent: 8/12/24 Proposal: 9/12/24
		RECONSTRUCTIVE TRANSPLANT (3)		
42.	FY24 Reconstructive Transplant Research Program (RTRP) (DoD/CDMRP) HT942524RTRPATDA (ATDA) HT942524RTRPIDA (IDA) HT942524RTRPIIRA (IIRA)	Three of the four anticipated awards have been posted: Advanced Technology Development Award, Idea Discovery Award, and Investigator-Initiated Research Award. All applications must address at least one of the Focus Areas and sub-bullets . https://cdmrp.health.mil/funding/rtrp	Up to \$1.5 million, for up to 3 years Dependent upon award mechanism	Pre-Application: 8/7/24 Proposal: 10/25/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		RESEARCH SUPPORT (1)		
43.	The NINDS Human Cell and Data Repository (U24 - Clinical Trial Not Allowed) (NIH/NINDS) RFA-NS-24-040	The repository will maintain the current collection of fibroblast and induced pluripotent stem cell (iPSC) lines as well as develop, characterize, expand source cells and iPSCs, and where appropriate, genetically modify new high-quality iPSC lines in accordance with the NINDS mission. The NINDS Human Cell and Data Repository will distribute human cell resources broadly to qualified academic and industry researchers to advance basic and translational research in neurological disorders. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-040.html	Up to \$915,000 per year, for up to 5 years	Letter of intent: 9/17/24 Proposal: 10/17/24
		SMALL BUSINESS DEVELOPMENT (9)		
44.	R&D that will contribute toward ARPA-H SBIR/STTR Program (GSA/ARPA-H) 47QFCA-24-R-0036	The following topic areas are included: Ambulatory Edema Monitor; Predictive Language Models for Cognitive Disability Adaptive Communication Tools; Cell and Gene Therapy Process Analytical Technology and Quality Control Testing; Wearable Cell sorting and Gene Delivery Systems; Precision Brain Targeting: non-invasive delivery at the right place and time; NutriTech: Revolutionizing Personalized Food as Medicine; Clinic-ready Imaging Devices and Protocols for Visualizing the Inner Ear with High Accuracy; and Advanced Continuously Wearable Blood Pressure Monitoring Technologies. https://sam.gov/opp/2879e06cc538421d9a2eb2c871a9537b/view	Dependent on research topic	Proposal: 7/26/24
45.	NSF Small Business Innovation Research / Small Business Technology Transfer Fast-Track Pilot Programs (SBIR-STTR Fast-Track) (NSF) NSF 24-582	The NSF SBIR/STTR Fast-Track programs provide non-dilutive, fixed amount cooperative agreements for the development of a broad range of technologies based on discoveries in science and engineering with the potential for societal and economic impacts. Small businesses applying to the NSF SBIR/STTR Fast-Track pilot programs must have a lineage of NSF research funding, at least one Senior/Key Personnel to have undergone formal customer discovery training, and the entire team must already be in place at the time of proposal submission. https://new.nsf.gov/funding/opportunities/nsf-small-business-innovation-research-small-1/nsf24-582/solicitation	Up to \$1,555,000, for up to 3 years	Project pitches accepted on a rolling basis through 3/5/25. Proposal: 9/18/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SMALL BUSINESS DEVELOPMENT		
46.	<p>PHS 2024-2 Omnibus Solicitations of the NIH, CDC, and FDA for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Grant Applications (NIH/CDC/FDA)</p> <p>PA-24-245 (R43/R44) PA-24-246 (R43/R44) PA-24-247 (R41/R42) PA-24-248 (R41/R42)</p>	<p>The SBIR program is intended to stimulate technological innovation in the private sector; strengthen the role of small business in meeting federal R/R&D needs; increase the commercial application of federally-supported research results; foster and encourage participation by socially and economically disadvantaged SBCs and women-owned business concerns in the SBIR program; and improve the return on investment from federally-funded research for economic and social benefits to the nation. The STTR program is intended to stimulate a partnership of ideas and technologies between innovative SBCs and non-profit research institutions through federally-funded R/R&D.</p> <p>https://grants.nih.gov/grants/guide/pa-files/PA-24-245.html (R43/R44) https://grants.nih.gov/grants/guide/pa-files/PA-24-246.html (R43/R44) https://grants.nih.gov/grants/guide/pa-files/PA-24-247.html (R41/R42) https://grants.nih.gov/grants/guide/pa-files/PA-24-248.html (R41/R42)</p>	<p>Up to \$306,872, for up to 1 year (Phase I) Up to \$2,045,816, for up to 2 years (Phase II) Certain topics may exceed these amounts</p>	<p>Multiple deadlines; NOFOs open through 4/5/25</p>
47.	<p>NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre-Clinical Research (R44 Clinical Trial Optional/Not Allowed) (NIH/NINDS)</p> <p>PAR-24-221 PAR-24-222</p>	<p>The goal of these NOFOs is to assist applicants in pursuing the next appropriate milestone(s) necessary to advance a product/technology that requires Federal regulatory approval or to bring a complex research tool to market. This opportunity aims to facilitate the transition of previously funded SBIR and STTR Phase II projects to the commercialization stage by promoting partnerships between NINDS SBIR or STTR recipients and third-party investors and/or strategic partners in the Phase IIB competing renewal.</p> <p>https://grants.nih.gov/grants/guide/pa-files/PAR-24-221.html https://grants.nih.gov/grants/guide/pa-files/PAR-24-222.html</p>	<p>Up to \$3 million, for up to 3 years</p>	<p>Multiple deadlines; NOFO open through 4/5/27</p>
48.	<p>Small Business Innovation Research and Small Business Technology Transfer Programs Phase I (USDA/NIFA)</p> <p>USDA-NIFA-SBIR-010774</p>	<p>The USDA SBIR/STTR programs focus on transforming scientific discovery into products and services with commercial potential and/or societal benefit. Projects dealing with agriculturally-related manufacturing and alternative and renewable energy technologies are encouraged across all SBIR/STTR topic areas. USDA SBIR/STTR's flexible research areas ensure innovative projects consistent with USDA's vision of a healthy and productive nation in harmony with the land, air, and water.</p> <p>https://www.nifa.usda.gov/grants/funding-opportunities/small-business-innovation-research-small-business-technology-transfer</p>	<p>Up to \$181,500 for 8 months</p>	<p>Proposal: 9/17/24</p>



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SMALL BUSINESS DEVELOPMENT		
49.	Pre-Announcement: DOE SBIR/STTR (DoE)	<p>Topics of this DoE SBIR/STTR release are anticipated to include: Complex Data: Advanced Data Analytic Technologies for Systems Biology and Bioenergy; Tools or Instruments for Structural or Morphological Characterization of Biological Systems Ranging from Atomic to Multi-Cellular Scales; Automated Bioimaging Devices for Structural and Functional Characterization of Plant and Microbial Communities; Quantum Enabled Bioimaging and Sensing Approaches for Bioenergy; and Delivery Technologies for Genetic Engineering Bioenergy Crops.</p> <p>https://science.osti.gov/-/media/sbir/pdf/funding/2024/FY25-Phase-I-Release-1-Topics07082024Updated.pdf</p>	<p>Up to \$250,000, for up to 1 year (Phase I) Up to \$1.6 million (Phase II)</p>	<p>Post date: 8/5/24 Letter of intent: 8/26/24 Proposal: 10/8/24</p>
		SUBSTANCE USE (8)		
50.	FY24 Alcohol and Substance Use Disorders Research Program Research Program (DoD/CDMRP) HT942524ASUDRPCA	<p>The Consortium Award supports a single operations center to solicit and provide oversight and management of basic research and clinical trials within the consortium.</p> <p>https://cdmrp.health.mil/funding/asudrp</p>	<p>Up to \$11.525 million, for up to 5 years</p>	<p>Pre-Application: 9/10/24 Proposal: 9/24/24</p>
51.	NOSI: Advancing Research on SUD with brain-based computational models (NIH/NIDA) NOT-DA-26-001	<p>This NOSI invites applications using computational modeling techniques to understand the neurobiology of substance use disorder (SUD)-relevant behavior and symptoms, to provide insights leading to SUD prevention and treatment.</p> <p>https://grants.nih.gov/grants/guide/notice-files/NOT-DA-26-001.html</p>	<p>Dependent upon proposal and award mechanism</p>	<p>Multiple deadlines; NOSI open through 9/7/27</p>
52.	Mechanistic Studies to Investigate the Interrelationship Between Sleep and/or Circadian Rhythms and Substance Use Disorders (R01 BESH Required/Clinical Trials Not Allowed) (NIH/NIDA) RFA-DA-25-044 (R01) RFA-DA-25-045 (R01)	<p>These NOFOs support basic science experimental studies involving humans and research project applications to expand our knowledge of the biological mechanisms and interrelationships between sleep/circadian rhythms and SUDs. These mechanistic studies will offer insights into the fundamental processes that link SUDs to sleep/circadian rhythms and vice-versa, and may also have implications for managing risks associated with developing SUDs and/or identifying new targets for prevention and therapeutics.</p> <p>https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-044.html (R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-045.html (R01)</p>	<p>Up to \$300,000 per year, for up to 5 years</p>	<p>Letter of intent: 9/29/24 Proposal: 10/29/24</p>



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SUBSTANCE USE		
53.	Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R41/R42/R43/R44 - Clinical Trial Optional) (NIH/NIDA) RFA-DA-25-049 (R41/R42) RFA-DA-25-050 (R43/R44)	These NOFOs encourage applications proposing research and development of accessible and affordable solutions targeted to improve health outcomes and reduce the impact of adverse health consequences of non-disordered drug use. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-049.html (R41/R42) https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-050.html (R43/R44)	Up to \$400,000, for up to 1 year (Phase I) Up to \$3 million, for up to 3 years (Phase II)	Letter of intent: 11/2/24 Proposal: 12/2/24
54.	Combined Neuromodulation and Behavioral Treatment Algorithm Development for Stimulant Use Disorder (StUD) Enriched for Vulnerable Phenotype (U01 Clinical Trial Required) (NIH/NIDA) RFA-DA-25-057	This NOFO supports the development of neuromodulatory devices with behavioral treatment component as a treatment for Stimulant Use Disorder (StUD). Given the high rates of relapse and poor treatment outcomes in StUD, the objective is to target patients with vulnerable phenotype including those with reported qualitatively high levels of impulsivity, compulsivity, and cognitive dysfunction. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-057.html	Up to \$500,000 per year, for up to 5 years	Letter of intent: 10/27/24 Proposal: 11/27/24
55.	Translational Resource Centers to Build Bridges Between Substance Use Epidemiology/Etiology and Prevention Intervention Research (U24 Clinical Trials Not Allowed) (NIH/NIDA) RFA-DA-25-085	This NOFO seeks innovative applications for a Translational Resource Center that will establish and support multidisciplinary research teams to conduct translational research between the fields of 1) substance use epidemiology and etiology and 2) substance use prevention intervention. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-085.html	Up to \$350,000 per year, for up to 4 years	Letter of intent: 10/13/24 Proposal: 11/13/24
		THERAPEUTICS (1)		
56.	Forecast: Facilitating Preclinical and Early Phase Human Studies for New Therapeutics (UG3/UH3 Clinical Trial Optional) (NIH/NIA) NOT-AG-24-025	This NOFO will invite applications on T1 translational aging research which focus on advancing new therapeutics from preclinical stages to first-in-human (FIH) trials for aging-related conditions such as sarcopenia, physical functional impairments, heart failure with preserved ejection fraction (HFpEF), and deficits such as immunosenescence. Biologics or stem/progenitor cell therapies for improving injury repair in older adults may be proposed. https://grants.nih.gov/grants/guide/notice-files/NOT-AG-24-025.html	Up to \$350,000 per year (UG3) Up to \$700,000 per year (UH3)	Estimated post date: 8/1/24 Estimated proposal date: 10/1/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		TOXIC EXPOSURES (3)		
57.	FY24 Toxic Exposures Research Program (TERP) (DoD/CDMRP) HT942524TERPCTA (CTA) HT942524TERPIIRA (IIRA) HT942524TERPTRA (TRA)	Three awards are included in the FY24 TERP: Clinical Trial Award, Investigator-Initiated Research Award, and Translational Research Award. All applications must address one or more of the FY24 TERP Program Goals and Topic Areas . https://cdmrp.health.mil/funding/terp	Up to \$2.5 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 8/13/24 Proposal: 11/7/24
		WARFIGHTER PERFORMANCE (1)		
58.	Alert WARfighter Enablement (AWARE) Phase 0 (DoD/DARPA) DARPA-PS-24-17	The AWARE program aims to develop a combination drug and device to non-invasively increase alertness following sleep loss in humans, without negative side effects such as anxiety, irritability, or euphoria, and with reduced addictive potential. https://sam.gov/opp/1d4409031eea4e2994dadd9c96a9fea8/view	Up to \$1.25 million, for up to 15 months	Abstract: 7/12/24 Oral Proposal Package: 7/31/24 Oral Proposal Presentation: 8/1-2/24





Recurring Opportunities

July 10, 2024

<https://www.g2gconsulting.com/gbg-reporting-service/>

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (4)		
59.	Office-Wide Innovative Solutions Opening for Resilient Systems Office (RSO) ARPA-H-SOL-24-103	RSO seeks solution summaries and proposals that drive innovations to enhance the adaptability, reliability, and interoperability of the health ecosystem. The following interest areas categorize the ground-breaking research we seek to support: Sociotechnical System Innovation; Health Ecosystem Integration; and Adaptive & Antifragile Solutions. https://sam.gov/opp/76679cd8810f40229694c60c0a593302/view	Dependent upon proposal and award mechanism	Solution Summaries: 3/3/25 Proposal: 3/15/25
60.	Office-Wide Innovative Solutions Opening for Health Science Futures (HSF) ARPA-H-SOL-24-104	HSF awardees will develop innovative technologies, tools, and platforms that can be applied to a broad range of diseases. The following interest areas define the ground-breaking research we seek to support: Breakthrough Technologies; Transformative Tools; and Platform Systems. https://sam.gov/opp/9a301dc812ba47268323e3130e381f19/view	Dependent upon proposal and award mechanism	Solution Summaries: 3/3/25 Proposal: 3/15/25
61.	Office-Wide Innovative Solutions Opening for Scalable Solutions Office (SSO) ARPA-H-SOL-24-105	ARPA-H SSO seeks solutions to improve the scalability and affordability of health care solutions, bridge gaps in underserved areas, and extend remote access to expertise by developing location-specific interventions, telemedicine solutions, and mobile health clinics. Solutions should focus on rapid innovation and the use of partnerships, as well as flexible distribution networks and streamlined manufacturing processes. SSO interest areas include: Scalable Technologies and Interventions; Collaborative Distribution Networks; and Biomanufacturing Innovations. https://sam.gov/opp/134cdc5d93b34c0ea39498055f315624/view	Dependent upon proposal and award mechanism	Solution Summaries: 3/3/25 Proposal: 3/15/25
62.	Office-Wide Innovative Solutions Opening for Proactive Health Office (PHO) ARPA-H-SOL-24-106	The Proactive Health Office (PHO) at ARPA-H is seeking solutions to improve the healthspan and health outcomes of Americans prior to the onset of disease and/or the development of diminished quality of life from illness. Interest areas include: Novel prevention, detection and prophylactic treatment methods for disease; Population-level approaches to increase the adoption of prevention and wellness behaviors; and System innovation for the delivery of proactive health outcomes. https://sam.gov/opp/53707a1538994e7d9ed8df8e5ee95ed1/view	Dependent upon proposal and award mechanism	Solution Summaries: 3/3/25 Proposal: 3/15/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AIR FORCE (3)		
63.	Airman Readiness Medical Research (ARMR) Hybrid BAA FA8650-20-S-6008	The Warfighter Medical Optimization Division intends to solicit White Papers under this announcement with the focus of conducting medical research in support of optimizing of the warfighter by enabling, enhancing, restoring, and sustaining the Airman to more effectively execute the Air Force mission. This medical research objective is dual natured: (1) ensure medical availability of Airmen by analyzing attributes (sensory, behavioral, physiologic) and operational environments (chemical, physical, psychological, biological, radiological stressors) to drive optimal performance of Airmen engaged in high-demand, high-impact mission tasks (2) investigate how the flight environment affects the process of life, the ability to maintain homeostasis, and the risk for injury or secondary insult, seeking to ameliorate these stressors to optimize Airman health and performance. https://www.grants.gov/search-results-detail/327332	Up to \$49 million, per award	White papers accepted on rolling basis until 5/1/25
64.	Research Interests of the Air Force Office of Scientific Research FA9550-23-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. These areas are organized and managed in two scientific Departments: Engineering and Information Science (RTA), Physical and Biological Sciences (RTB), and our international offices (EAORD, SOARD, and AOARD). https://www.grants.gov/search-results-detail/345653	Dependent upon proposal, for up to 5 years	White papers accepted on a rolling basis
65.	Research Interests of the United States Air Force Academy USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions. https://www.grants.gov/search-results-detail/330175	Dependent upon proposal, for up to 5 years	Proposals accepted on a rolling basis
		ARMY (8)		
66.	The Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense Broad Other Transaction Authority Announcement (BOTAA) BOTAA-24-01	JPEO-CBRND is interested in efforts directed toward the development of enabling technologies that speed up the advanced development process. Areas of interest include: Software and Artificial Intelligence (AI), wearable sensors, threat detection, biothreat containment and aeromedical evaluation. https://sam.gov/opp/2d04622b25364669857a6a61c576ade9/view	Dependent upon proposal	Preproposals accepted through 2/7/29



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY		
67.	BAA R&D in Support of the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB CBRND-BAA-22-01	The JPMO is interested in studies on new and better ways to develop medical CBRN countermeasures more rapidly and with increased efficiency through enabling technologies, life cycle bioinformatics, and improved logistics tracking. Mission areas include: Biological Medical Prophylaxis; Medical, Chemical, and Biological Countermeasures; Medical Radiological Countermeasures; Medical Diagnostic and Surveillance Systems; and Enabling Biotechnologies and Response Systems. https://sam.gov/opp/f2d01f5a6c444e32af543e9519a0805f/view	Dependent upon proposal	Proposals accepted on a rolling basis through 6/11/27
68.	USAMRDC Broad Agency Announcement for Extramural Medical Research HT9425-23-S-BAA1	R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease; Combat Casualty Care; and Military Operational Medicine. https://www.grants.gov/search-results-detail/343725	Dependent upon proposal, for up to 5 years	Pre-applications accepted until 9/30/27 Full proposal by invitation
69.	USSOCOM BAA for Extramural Biomedical and Human Performance Research and Development HT9425-23-S-SOC1	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries; PFC; human performance optimization; canine medicine/performance; brain health; immune response; automation of systematic reviews and metanalysis; and novel post-traumatic stress, depression, and anxiety treatment. SOF medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. https://www.grants.gov/search-results-detail/349586	Dependent upon proposal	Proposals accepted through 7/31/28 Submission of a pre-proposal is required
70.	Army Research Office Laboratory Broad Agency Announcement for Foundational Research W911NF-23-S-0001	ARL's foundational research mission spans basic research and applied research but may include advanced technology development and advanced component development and prototypes when opportunities arise to directly or indirectly help achieve ARL's mission. Topics include Biotronics, Genetics, and Neurophysiology of Cognition; the full list of research topics is available here: https://www.arl.army.mil/opportunities/arl-baa/ https://sam.gov/opp/7560e5d4024b4e94ad3eab6180cfcc36/view	Dependent upon proposal	Proposals accepted on a rolling basis until 11/20/27
71.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic, Applied, and Advanced Research W911NF-23-S-0010	ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology. https://sam.gov/opp/ee8d9ecec4f94269b6e1ac16b09d9417/view	Dependent upon proposal	Proposals accepted on a rolling basis until 4/30/28 Full proposal required



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY		
72.	Army Applications Lab BAA for Disruptive Applications W911NF-24-S-0008	AAL is seeking technologies that address a wide range of Army needs consistent with CFT capability focus areas and associated programs and lines of effort as well as potentially disruptive new capabilities that augment or enhance Army capability overmatch. https://sam.gov/opp/3f8ec6d36d584ca28364a2f8a10255b7/view	Dependent upon proposal	Proposals accepted through 4/4/29 Pre-proposal is required
73.	Army Combat Capabilities Development Command Broad Agency Announcement W911QY20R0022	Broad Agency Announcement Solicitation for the US Army Combat Capabilities Development Command - Soldier Center (CCDC-SC). Please see the BAA solicitation document for the submission instructions and areas of interest. https://www.grants.gov/search-results-detail/327285	Dependent upon proposal	Proposals accepted on a rolling basis until 2/28/25
		BARDA (2)		
74.	BARDA Broad Agency Announcement BAA-23-100-SOL-00004	BARDA is accepting proposals related to diagnostics and POC tests for COVID and other MCM topics that include: CBRN Vaccines, Antivirals & Antitoxins; Antimicrobials; Radiological/Nuclear MCMs; Chemical Threat MCMs; Burn and Blast Medical MCMs; Diagnostics; Influenza & Emerging Diseases vaccines and therapeutics; ImmuneChip+; Flexible and Strategic Therapeutics (FASTx). https://sam.gov/opp/764c53aa6dac43538ef902a2bc2af44f/view	Dependent upon proposal	Proposal: 9/25/28
75.	BARDA DRIVe EZ-BAA DRIVeEZBAA22100SOL00003	BARDA is currently accepting submissions through the EZ-BAA for two AOIs: AOI #17: Digital MCMs; AOI #26: Agnostic Diagnostic. https://sam.gov/opp/4ab24f470f6f4cad84ad1bb2065d35ea/view	Up to \$750,000 per award	Proposals accepted on a rolling basis Deadlines vary by AOI
		DARPA (2)		
76.	Biological Technologies BAA HR001123S0045	Research in BTO creates biotechnological capabilities that provide tactical care and restore function to injured warfighters, increase operational resilience, develop novel functional materials, and detect and protect against threats to maintain force readiness. BTO is interested in submissions related to the following topic areas: Human Performance; Materials, Sensors, Processing; Ecosystem and Environmental; Biosecurity and Biosafety; and Biomedical and Biodefense. https://sam.gov/opp/597bf60984314db1b3ecf393677c75/view	Dependent upon proposal	Abstracts & proposals accepted on a rolling basis until 9/19/24
77.	Defense Sciences Office, Office-wide HR001123S0053	The DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: Novel Materials & Structures; Sensing and Measurement; Computation and Processing; Enabling Operations; Collective Intelligence; and Emerging Threats. https://sam.gov/opp/972be70efd7e4608b01311466edf6bof/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 9/26/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DEFENSE THREAT REDUCTION AGENCY (3)		
78.	Fundamental Research to Counter Weapons of Mass Destruction (C-WMD) HDTRA1-14-24-FRCWMD-BAA	DTRA seeks to identify, adopt, and adapt emerging, existing and revolutionary sciences that may demonstrate high payoff potential to Counter-WMD (C-WMD) threats. Current thrust areas include global biosurveillance, biosafety, and biosecurity, and chemical and biological defense. https://sam.gov/opp/3b8216acdcc44c46ada2511459918de5/view	Up to \$1 million per year, for up to 5 years	White papers accepted through 9/2024
79.	Research and Development Innovations Broad Agency Announcement HDTRA1-22-S-0003	DTRA seeks proposals that will advance research, development, test, and evaluation (RDT&E) priorities across five interrelated thrust areas derived from the 2022 DTRA Strategic Plan for RDT&E : <ul style="list-style-type: none"> • Understand current and emerging WMD situations, threats, and capabilities • Enable effective and integrated WMD deterrence • Control, disable, and defeat current and emerging WMD threats • Protect the force and mitigate crises from WMD • Enable cross-cutting capabilities https://sam.gov/opp/45f3e82bc46c4d3f89560b700d1123cd/view	Dependent upon proposal, for up to 18 months	White papers accepted on a rolling basis through 2/14/27
80.	Biological Threat Reduction with Global Partners Broad Agency Announcement (BAA) HDTRA1-24-S-0002	BTRP supports international health security efforts to address diseases caused by U.S. Biological Select Agents, pathogens of pandemic potential, and emerging infectious diseases. BTRP achieves its mission through collaboration with partner countries and the international community to minimize the threat of deliberate, accidental, and natural infectious disease outbreaks through enhanced detection, diagnosis, and reporting capabilities and biosecurity and biosafety measures. https://www.grants.gov/search-results-detail/353860	Dependent upon proposal and award mechanism	Proposal: 4/28/29
		DEPARTMENT OF ENERGY (1)		
81.	FY 2024 Continuation of Solicitation for the Office of Science Financial Assistance Program DE-FOA-0003177	By integrating genome science with advanced computational and experimental approaches, the Division seeks to gain a predictive understanding of living systems, from microbes and microbial communities to plants and ecosystems. This foundational knowledge enables design and reengineering of microbes and plants underpinning a broad clean energy and bioeconomy portfolio. https://www.grants.gov/search-results-detail/350408	Dependent upon award mechanism	Proposals accepted on a rolling basis through 9/30/24
		NAVY (3)		
82.	Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology N0001424SB001	The ONR, ONR Global, and Marine Corps Warfighting Lab are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. https://www.nre.navy.mil/work-with-us/funding-opportunities/fy24-long-range-broad-agency-announcement-baa-navy-and-marine	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		NAVY		
83.	NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research N00173-24-S-BA01	The Naval Research Laboratory is seeking to advance technology developed for in vitro diagnostic devices that are amenable to military hardening and integration with communication capabilities to support the medical diagnostic and epidemiological detection and biosurveillance needs of the US military across multiple Echelons of Care and specifically for field deployment at Echelons 1 or 2. https://sam.gov/opp/1e5fbd8c66d949fdb4cfe0afc8bob76b/view	Dependent upon proposal and award mechanism	White papers accepted through 12/31/24
84.	FY24 Broad Agency Announcement for Innovative Environmental Technologies and Methodologies N3943024S2000	This announcement seeks out technologies and methodologies to reduce environmental impacts from current and past Navy operations, and applies to Navy installations worldwide. NEXWC is interested in environmental technologies and methodologies that are either new, innovative, advance the state-of-the art, or increase knowledge or understanding of a technology or methodology. https://sam.gov/opp/2397c9059c3942cfb618400b2d8637e2/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 4/7/25
		NATIONAL SCIENCE FOUNDATION (1)		
85.	Small Business Innovation Research Program Phase I (SBIR/STTR Phase I) NSF 24-579	The NSF SBIR and STTR programs focus on transforming scientific discovery into products and services with commercial potential and/or societal benefit. Unlike fundamental or basic research activities that focus on scientific and engineering discovery itself, the NSF SBIR program supports the creation of opportunities to move fundamental science and engineering out of the lab and into the market or other use at scale, or startups and small businesses representing "deep technology ventures." The programs fund research and development, and are designed to provide non-dilutive funding and entrepreneurial support at the earliest stages of company and technology development. The required Project Pitch allows startups and small businesses to get quick feedback at the start of their application for Phase I funding. View the full list of topics here . https://new.nsf.gov/funding/opportunities/nsf-small-business-innovation-research-small-o/nsf24-579/solicitation	Up to \$275,000 for up to 1 year	Project pitches accepted on a rolling basis through 3/5/25.





Terms

AD/ADRD: Alzheimer's Disease / Alzheimer's Disease Related Dementias

Aoi: Area of Interest

BAA: Broad Agency Announcement

BBB: Blood-Brain Barrier

CNS: Central Nervous System

FOA: Funding Opportunity Announcement

IC: NIH Institutes and Centers

NOFO: Notice of Funding Opportunity

NOSI: Notice of Special Interest

PI: Principal Investigator

PTSD: Post-Traumatic Stress Disorder

RFI: Request for Information

RFP: Request for Proposal

SBIR: Small Business Innovation Research

SDOH: Social Determinants of Health

STTR: Small Business Technology Transfer

SUD: Substance Use Disorder

TRL: Technology Readiness Level

VCID: Vascular Contributions to Cognitive Impairment and Dementia

Agencies

ARPA-H: Advanced Research Projects Agency for Health

ASPR: Administration for Strategic Preparedness and Response

BARDA: Biomedical Advanced Research and Development Authority

CDC: Centers for Disease Control and Prevention

CDMRP: Congressionally Directed Medical Research Programs

DARPA: Defense Advanced Research Projects Agency

DHA: Defense Health Agency

DoD: Department of Defense

FDA: U.S. Food and Drug Administration

MTEC: Medical Technology Enterprise Consortium

NIH: National Institutes of Health

[Back to Table of Contents](#)

GBG Acronyms

Updated Monthly

July 10, 2024

<https://www.g2gconsulting.com/gbg-reporting-service/>

NSF: National Science Foundation

PCORI: Patient-Centered Outcomes Research Institute

USAMRDC: U.S. Army Medical Research and Development Command

USAMRIID: U.S. Army Medical Research Institute of Infectious Diseases

USSOCOM: United States Special Operations Command

NIH Institutes and Centers

CC: NIH Clinical Center

CIT: NIH Center for Information Technology

CSR: NIH Center for Scientific Review

FIC: Fogarty International Center

NCATS: National Center for Advancing Translational Sciences

NCCIH: National Center for Complementary and Integrative Health

NCI: National Cancer Institute

NEI: National Eye Institute

NHGRI: National Human Genome Research Institute

NHLBI: National Heart, Lung, and Blood Institute

NIA: National Institute on Aging

NIAAA: National Institute on Alcohol Abuse and Alcoholism

NIAID: National Institute of Allergy and Infectious Diseases

NIAMS: National Institute of Arthritis & Musculoskeletal & Skin Diseases

NIBIB: National Institute of Biomedical Imaging and Bioengineering

NICHD: Eunice Kennedy Shriver National Institute of Child Health and Human Development

NIDA: National Institute on Drug Abuse

NIDCD: National Institute on Deafness and Other Communication Disorders

NIDCR: National Institute of Dental and Craniofacial Research

NIDDK: National Institute of Diabetes and Digestive and Kidney Diseases

NIEHS: National Institute of Environmental Health Sciences

NIGMS: National Institute of General Medical Sciences

NIMH: National Institute of Mental Health

NIMHD: National Institute on Minority Health and Health Disparities

NINDS: National Institute of Neurological Disorders and Stroke

NINR: National Institute of Nursing Research

NLM: National Library of Medicine

